Mesothelioma Staging

Mesothelioma Staging
TNM 9th Edition (Effective January 1, 2025)
Current System	AJCC/UICC TNM 9th Edition
Key Innovation	Psum (pleural thickness)
Database	3,598 patients, 29 centers
Stage I Median OS	~21 months
Stage IV Median OS	~12 months
Peritoneal Staging	PCI (0–39)
Free Case Review →

Mesothelioma Staging

Overview

Mesothelioma staging determines the anatomic extent of disease at diagnosis, guides treatment decisions, and provides a framework for predicting survival. The 9th edition TNM staging system, published in late 2024 and effective January 1, 2025, represents the most significant revision in mesothelioma staging history. For the first time, quantitative tumor size criteria — specifically the sum of pleural thickness measurements at three axial CT levels (Psum) — replace the purely qualitative invasion-based approach used since 1994. This change was driven by a database of 3,598 patients from 29 centers across 4 continents, with only 36.4% undergoing curative-intent surgery, reflecting the real-world shift toward nonsurgical management. Peritoneal mesothelioma uses the Peritoneal Cancer Index (PCI) as a de facto staging tool, while pericardial and testicular mesothelioma have no formal staging systems due to their extreme rarity. Understanding disease stage is critical for patients and families to make informed treatment and legal decisions within applicable filing deadlines.

Mesothelioma staging at a glance:

• 9th edition TNM replaces invasion-based staging with tumor thickness — quantitative Psum measurements at three CT levels replace subjective criteria used since 1994
• Psum cutpoints define clinical T categories — cT1 ≤12 mm, cT2 >12–30 mm, cT3 >30 mm, identified through recursive partitioning of 3,598 patients
• Stage I patients survive approximately 21 months — with 75% one-year and 33% five-year survival rates
• Stage IV drops to approximately 12 months — with 52% one-year and just 4% five-year survival
• Clinical and pathological T staging differ for the first time — because Psum cannot be measured after surgery, clinical staging uses thickness while pathological staging uses invasion
• Three previously-used descriptors were eliminated — non-transmural diaphragm invasion, lung parenchyma invasion, and endothoracic fascia invasion could not be reliably assessed on CT
• Fissural invasion was reclassified from pT1 to pT2 — validated by an external study of 818 patients showing 17 versus 25.8 months median survival
• Peritoneal PCI scores predict surgical outcomes — PCI ≤19 is associated with improved survival (p=0.001) across 13 abdominopelvic regions
• Only 36.4% of patients in the database had surgery — reflecting the real-world shift toward nonsurgical management and making staging applicable to all patients

Key Facts

Key Facts: Mesothelioma Staging

9th Edition TNM (2025): First staging system to incorporate quantitative tumor thickness (Psum) into clinical T categories, replacing subjective invasion-based criteria used since 1994 Psum Cutpoints: cT1 ≤12 mm; cT2 >12–30 mm; cT3 >30 mm — identified through recursive partitioning analysis across 3,598 patients Three Descriptors Eliminated: 9th edition removed non-transmural diaphragm invasion, lung parenchyma invasion, and endothoracic fascia invasion — none reliably assessed on CT Clinical ≠ Pathological T: For the first time in any TNM system, clinical and pathological T staging are not directly linked because Psum cannot be measured after surgery Fissural Invasion Reclassified: Moved from pT1 to pT2, validated by 818-patient external study showing 17 months vs. 25.8 months median survival Stage I Survival: Approximately 75% at 1 year and 33% at 5 years for the earliest-stage disease Stage IV Survival: Approximately 52% at 1 year and 4% at 5 years for metastatic disease Peritoneal PCI: Abdomen divided into 13 regions scored 0–3 each; total 0–39; PCI ≤19 associated with improved survival (p=0.001) Database Shift: Only 36.4% of 9th edition database patients had surgery (down from 64.5% in 7th edition), making staging criteria more applicable to all patients N Categories Unchanged: 9th edition analysis confirmed 8th edition nodal categories remain prognostically valid — cN0 median 23.2 months vs. cN1 18.5 months

How Has Mesothelioma Staging Evolved?

Mesothelioma staging has undergone substantial transformation over five decades, progressing from simple surgical observations to an internationally validated, measurement-based system.

The Butchart System (1976)

The oldest mesothelioma staging system was proposed by Eric Butchart based on a small surgical series, developed before the widespread availability of CT imaging.

Butchart Stage	Definition
I	Tumor confined to the ipsilateral pleura, lung, and pericardium
II	Tumor invading chest wall, mediastinal structures, or thoracic lymph node involvement
III	Tumor penetrating diaphragm to involve peritoneum, or extra-thoracic lymph node involvement
IV	Distant hematogenous metastases

Despite its simplicity, the Butchart system remarkably parallels current staging concepts. However, it is no longer used clinically because it was based on a small sample and developed before modern cross-sectional imaging.

The Brigham System (Sugarbaker)

Developed by Dr. David Sugarbaker at Brigham and Women's Hospital, this system focused on surgical resectability and lymph node involvement rather than anatomic extent.

Brigham Stage	Definition
I	Resectable tumor, no lymph node involvement
II	Resectable tumor, lymph nodes involved
III	Unresectable — tumor extends into chest wall, heart, diaphragm, or peritoneum
IV	Distant metastatic disease

The Brigham system was never widely adopted because its focus on resectability made it relevant only to surgical candidates and departed from standard TNM anatomic staging principles.

The IMIG/TNM System (1994–Present)

In 1994, the International Mesothelioma Interest Group (IMIG) and the IASLC proposed a formal TNM-based staging system, subsequently adopted by the AJCC and UICC.

Edition	Era	Key Features	Surgical %
6th/7th	1994–2016	Separate T1a (parietal) and T1b (parietal + visceral); purely invasion-based	64.5%
8th	2018	Collapsed T1a/T1b into single T1; first exploratory analysis of pleural thickness	52.7%
9th	2025	Psum size criteria for clinical T; three descriptors eliminated; clinical ≠ pathological T	36.4%

The progressive decrease in surgical patients across editions — from 64.5% to 36.4% — reflects the real-world shift toward nonsurgical management and makes the 9th edition staging criteria more representative of all mesothelioma patients.

What Are the 9th Edition Clinical T Categories?

The landmark change in the 9th edition is the incorporation of Psum — the sum of maximum pleural thickness measured at three axial CT levels — into clinical T descriptors. This replaces the purely qualitative invasion criteria used since 1994 with objective, reproducible measurements.

Category	Psum Criteria	Invasion Criteria	Description
cT1	≤12 mm	No fissural involvement	Earliest clinical disease — thin pleural tumor on ipsilateral pleura
cT2	≤12 mm with local invasion, OR >12–30 mm regardless	Fissural involvement, mediastinal fat, or single chest wall focus (if Psum ≤12 mm)	Moderate disease — thickness-based OR invasion-based qualification
cT3	>30 mm	—	Bulky disease defined purely by thickness measurement
cT4	Any	Chest wall bone, mediastinal organs, through diaphragm/pericardium, contralateral pleura, pericardial effusion	Locally advanced disease with organ invasion

The Psum cutpoints of 12 mm and 30 mm were identified through recursive partitioning analysis and validated across geographic regions and histologic types.

Three Eliminated 8th Edition Descriptors

The 9th edition removed three qualitative descriptors that cannot be accurately determined on CT imaging:

1. Non-transmural diaphragm invasion (formerly cT2) — radiologists cannot reliably distinguish partial from complete diaphragm involvement
2. Invasion of lung parenchyma (formerly cT2) — difficult to differentiate from atelectasis or entrapment on imaging
3. Endothoracic fascia invasion (formerly cT3) — not a discrete anatomic structure identifiable on CT

This simplification acknowledges that prior T descriptors, developed through surgical databases, do not translate reliably to radiologic assessment in an era when most patients never undergo surgery.

How Does Pathological T Staging Differ in the 9th Edition?

A groundbreaking concept in the 9th edition: clinical and pathological T staging are not directly linked. This is unprecedented in TNM staging for any solid cancer.

Why they diverge: Psum measures pleural thickness on intact CT images, but surgeons typically remove mesothelioma in pieces during extended pleurectomy/decortication, making post-surgical thickness measurement impossible. There is no reproducible pathological counterpart for Psum.

Key Pathological T Change: Fissural Invasion

The single major pathological T revision is the reclassification of fissural invasion from pT1 to pT2.

An external validation study of 818 patients confirmed this change:

• 325 patients initially classified as pT1 were reclassified to pT2 due to fissural invasion
• Patients with fissural invasion: median survival 17 months
• Patients without fissural invasion: median survival 25.8 months
• Cox regression confirmed 9th edition pT staging was a strong prognostic factor, whereas 8th edition pT staging was not prognostic for distinguishing T1 from T2

Clinical Significance: The separation of clinical and pathological T means that a patient staged as cT1 before surgery may be restaged as pT2 after pathologic examination reveals fissural invasion. Treatment teams must consider both staging tracks when interpreting outcomes and planning adjuvant therapy.

What Are the N and M Categories?

N Categories (Regional Lymph Nodes)

The IASLC analyzed nodal involvement in the 9th edition database and concluded the 8th edition categories remain prognostically valid.

Category	Definition	Median OS (Clinical)	Median OS (Pathological)
N0	No regional lymph node metastasis	23.2 months	33.8 months
N1	Metastasis to ipsilateral intrathoracic lymph nodes (bronchopulmonary, hilar, mediastinal)	18.5 months	25.0 months
N2	Metastasis to contralateral intrathoracic or any supraclavicular lymph nodes	Shorter	Shorter

Resected pN0 patients achieved a 3-year overall survival of 48%. No survival difference was found between single-station and multiple-station nodal metastases.

M Categories (Distant Metastasis)

Category	Definition
M0	No distant metastasis
M1	Distant metastasis (bones, contralateral lung/pleura, peritoneum, liver, other organs)

The evidence-based analysis confirmed the 8th edition M descriptors. No changes were proposed for the 9th edition.

What Are the 9th Edition Stage Groupings?

The revised stage groupings combine the new T categories with unchanged N and M criteria:

Stage	TNM Combinations	Key Change from 8th Edition	Clinical Significance
I	T1 N0 M0	Merged former IA/IB into single Stage I	Earliest tumors only: Psum ≤12 mm, no fissural involvement
II	T2 N0 M0; T1 N1 M0	T2 now covers Psum >12–30 mm or fissural/mediastinal involvement	Includes slightly more advanced tumors and early nodal disease
IIIA	T2 N1 M0; T3 N0-1 M0; T1-3 N2 M0	Boundaries shifted based on thickness characteristics	Includes all N2 disease and bulky tumors; borderline surgical candidacy
IIIB	T4 any N M0	Locally advanced unresectable disease	Organ invasion (chest wall bone, mediastinal structures, contralateral pleura)
IV	Any T, any N, M1	Unchanged	Distant metastatic disease

"Understanding mesothelioma staging — particularly the distinction between resectable and unresectable disease — is essential when evaluating legal options. Stage at diagnosis directly impacts the urgency of filing claims, because compensation timelines are governed by statutes of limitations that begin at diagnosis regardless of prognosis."

— Rod De Llano, Senior Partner, Danziger & De Llano

How Is Pleural Thickness (Psum) Measured?

The standardized measurement protocol for the 9th edition provides objective, reproducible criteria applicable across hospitals and countries:

Step 1: Obtain a CT scan in the axial plane

Step 2: Divide the hemithorax into three equal vertical sections — upper third, middle third, and lower third

Step 3: Measure maximum pleural thickness at one representative level within each section

Step 4: Sum the three measurements to calculate Psum (in millimeters)

Psum Value	Clinical T Category	Interpretation
≤12 mm	cT1 (if no fissural involvement)	Low tumor burden
>12 to ≤30 mm	cT2	Intermediate tumor burden
>30 mm	cT3	High tumor burden (bulky disease)

Additionally, Fmax (maximum thickness at the fissure) greater than 5 mm indicates poor prognosis and contributes to fissural invasion assessment.

Why Psum Matters: Previous staging relied entirely on qualitative assessments of invasion (e.g., "does the tumor invade the diaphragm?") that were subjective and inconsistent between radiologists. Psum provides a number that any radiologist at any hospital can measure the same way, dramatically improving staging reproducibility and enabling meaningful comparison across institutions and clinical trials.

How Is Peritoneal Mesothelioma Staged?

Peritoneal mesothelioma has no universally accepted TNM staging system due to insufficient case volumes for validation. The Peritoneal Cancer Index (PCI) serves as the de facto staging tool, particularly for surgical planning.

How PCI Works

• The abdomen is divided into 13 regions
• Each region is scored 0 to 3 based on tumor burden: 0 = no visible disease; 1 = tumor ≤0.5 cm; 2 = tumor >0.5–5 cm; 3 = tumor >5 cm or bowel involvement
• Total PCI score range: 0–39

PCI Score	Equivalent Stage	Surgical Candidacy	Prognosis
1–10	Stage 1	Best candidates for CRS/HIPEC	Favorable
11–20	Stage 2	CRS/HIPEC may be beneficial	Intermediate
21–30	Stage 3	Marginal surgical candidacy	Guarded
31–39	Stage 4	Generally not surgical candidates	Poor

PCI ≤19 is associated with improved overall survival (p=0.001), while PCI ≥30 is associated with worse survival (p=0.002).

Pericardial and Testicular Mesothelioma

No formal staging systems exist for pericardial or testicular mesothelioma. These exceptionally rare variants (combined less than 5% of all mesothelioma cases) lack sufficient case volumes to develop and validate staging systems. Physicians characterize disease extent descriptively using imaging and surgical findings.

What Is the Survival by Stage?

Pleural Mesothelioma Survival by TNM Stage

Stage	1-Year Survival	2-Year Survival	5-Year Survival	Median OS
Stage I	75%	41%	33%	~21 months
Stage II	70%	39%	9%	~19 months
Stage III	62%	29%	6%	~16 months
Stage IV	52%	24%	4%	~12 months

Source: NCI SEER database; American Cancer Society

SEER Summary Stage Survival

SEER Stage	5-Year Relative Survival
Localized	18%
Regional	11%
Distant	7%
All stages combined	12%

Source: NCI SEER database

Peritoneal Mesothelioma Survival by Treatment

Treatment	1-Year	3-Year	5-Year	Median Survival
CRS + HIPEC (CC-0)	83%	62%	52%	33–103 months
All peritoneal (SEER)	92%	74%	65%	3–5 years

Source: NCI SEER database; Mesothelioma.net

How Does Stage Determine Treatment?

For treatment purposes, mesothelioma staging is often simplified into a binary classification: resectable versus unresectable disease.

Stage	Typical Treatment Approach	Resectability
I–II	Surgery (P/D or EPP) + adjuvant chemotherapy ± radiation; immunotherapy may be added	Generally resectable
IIIA	Case-by-case: neoadjuvant chemo/immunotherapy followed by surgery, or definitive chemo-immunotherapy	Borderline — depends on tumor extent, histology, patient fitness
IIIB	First-line nivolumab + ipilimumab (CheckMate 743 standard); pemetrexed/cisplatin; or clinical trial	Unresectable
IV	Systemic therapy (immunotherapy or chemotherapy); palliative care; clinical trials	Unresectable

The 9th edition's improved prognostic discrimination is particularly valuable for clinical trials, enabling more homogeneous treatment arms and consistent enrollment criteria across international sites through standardized Psum measurement.

Important: Mesothelioma staging determines not only treatment options but also the urgency of pursuing legal remedies. Statutes of limitations for mesothelioma lawsuits typically range from 1 to 6 years from diagnosis and run regardless of disease stage or treatment outcome. Even patients with early-stage, resectable disease should promptly consult with experienced mesothelioma attorneys to preserve all legal options.

Frequently Asked Questions

What staging system is currently used for mesothelioma?

The TNM 9th edition (AJCC/UICC), effective January 1, 2025, is the current international standard for pleural mesothelioma staging. It is the first version to incorporate quantitative pleural thickness measurements (Psum) into clinical T categories. Peritoneal mesothelioma uses the Peritoneal Cancer Index (PCI), and pericardial/testicular mesothelioma have no formal staging systems.

What is Psum and why does it matter?

Psum is the sum of maximum pleural thickness measured at three axial CT levels (upper, middle, and lower hemithorax). Cutpoints of 12 mm and 30 mm define clinical T categories. Psum matters because it provides an objective, reproducible number that any radiologist at any hospital can measure, replacing the subjective invasion-based criteria that varied between observers.

What is the difference between clinical and pathological staging?

Clinical staging is based on imaging (primarily CT) and determines the treatment plan before surgery. Pathological staging is based on examination of tissue removed during surgery. In the 9th edition, clinical and pathological T staging are not directly linked — Psum measures thickness on intact CT images, but surgical removal in pieces makes post-surgical thickness measurement impossible.

Can mesothelioma be diagnosed at an early stage?

Early-stage diagnosis is possible but uncommon because mesothelioma symptoms (shortness of breath, chest pain) typically develop only after the disease has progressed. Only about 20% of patients are diagnosed at a localized stage. Early detection through screening of high-risk populations (including those with significant asbestos exposure history) and advances in imaging technology may improve early-stage diagnosis rates.

What is the survival rate for Stage I mesothelioma?

Stage I mesothelioma has the best prognosis, with approximately 75% survival at 1 year, 41% at 2 years, and 33% at 5 years. Median overall survival is approximately 21 months. Individual outcomes depend on additional factors including histologic subtype, performance status, age, and treatment approach.

How is peritoneal mesothelioma staged?

Peritoneal mesothelioma uses the Peritoneal Cancer Index (PCI), which divides the abdomen into 13 regions, each scored 0–3 based on tumor burden (total range 0–39). PCI ≤19 is associated with improved survival. Unlike pleural mesothelioma, there is no formal TNM staging system for peritoneal disease, though a proposal to map PCI to T categories (Yan et al., 2011) exists but has not been widely adopted.

Does staging affect eligibility for clinical trials?

Yes. Clinical trials specify stage-based eligibility criteria, and the 9th edition's standardized Psum measurement enables more consistent enrollment criteria across international sites. Better T-category stratification ensures more homogeneous treatment arms. Some trials are restricted to early-stage (resectable) patients, while others focus specifically on advanced-stage (unresectable) disease.

Why were three staging descriptors removed in the 9th edition?

The 9th edition eliminated non-transmural diaphragm invasion, lung parenchyma invasion, and endothoracic fascia invasion from clinical T descriptors because these features cannot be reliably identified on CT imaging. Since most patients now undergo staging with imaging rather than surgery, the criteria needed to reflect what radiologists can actually assess.

Quick Statistics

• 3,598 patients from 29 centers across 4 continents formed the database for the 9th edition TNM revision
• 36.4% of 9th edition database patients underwent curative-intent surgery, down from 64.5% in the 7th edition
• 12 mm and 30 mm Psum cutpoints define the three clinical T categories (cT1, cT2, cT3) in the 9th edition
• 25.8 vs. 17 months median survival for patients without versus with fissural invasion, validating the pT1-to-pT2 reclassification
• 23.2 vs. 18.5 months median overall survival for cN0 versus cN1 disease
• 75% vs. 52% one-year survival for Stage I versus Stage IV pleural mesothelioma
• 33% vs. 4% five-year survival for Stage I versus Stage IV disease
• 18% five-year relative survival for localized disease versus 7% for distant disease (SEER summary staging)
• PCI ≤19 associated with improved overall survival in peritoneal mesothelioma (p=0.001)

Get Help

If you or a loved one has been diagnosed with mesothelioma at any stage, understanding staging is a critical step toward making informed treatment and legal decisions. Staging determines both treatment options and the timeline for pursuing compensation.

Legal Resources:

• Danziger & De Llano — Experienced mesothelioma attorneys offering free case evaluations. Call (866) 222-9990 for a confidential consultation.
• Mesothelioma Lawyers Near Me — Find qualified mesothelioma attorneys in your area and access the free case evaluation quiz.
• Mesothelioma Lawyer Center — Legal resources and attorney matching services for mesothelioma families.

Related Pages

Medical Information:

• Mesothelioma_Diagnosis_and_Staging — Comprehensive guide to diagnosis process and staging overview
• Mesothelioma_Prognosis — Prognostic scoring systems, BAP1 mutations, and survival prediction
• Mesothelioma_Survival_Statistics — Population-level survival data and treatment outcomes
• Understanding_Your_Diagnosis — Guide to mesothelioma types and diagnosis
• Mesothelioma_Treatment_Centers — Specialized cancer centers with mesothelioma programs
• Clinical_Trials — Current research studies and enrollment opportunities
• CheckMate_743_Trial — Immunotherapy trial data for unresectable disease

Quick Reference:

• Mesothelioma_Quick_Facts — Core statistics and essential data
• Veterans_Mesothelioma_Quick_Reference — VA benefits and military exposure data

Legal Resources:

• Mesothelioma_Claim_Process — Steps from diagnosis to compensation
• Statute_of_Limitations_by_State — State-by-state filing deadlines
• Asbestos_Trust_Funds — Trust fund information and filing guidance